SNY - Sanofi
After hours:
Chart Events
Fast Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 51.54 |
| Open | 51.21 |
| Bid | 51.09 x 800 |
| Ask | 52.41 x 1100 |
| Day's Range | 51.10 - 51.33 |
| 52 Week Range | 36.91 - 57.82 |
| Volume | |
| Avg. Volume | 1,686,847 |
| Market Cap | 127.985B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 14.19 |
| EPS (TTM) | 3.61 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.90 (3.74%) |
| Ex-Dividend Date | May 30, 2023 |
| 1y Target Est | 63.38 |
Fair Value
Related Research
ZacksFDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody
The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.
ZacksInnate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Innate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.
BenzingaUnanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The committee also voted 19 to 2 in support of nirsevimab's favorable benefit-risk profile for children up to 24 months of age who remain vulnerable to
ZacksSanofi (SNY) Outpaces Stock Market Gains: What You Should Know
Sanofi (SNY) closed at $51.54 in the latest trading session, marking a +1.3% move from the prior day.
GlobeNewswirePress Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab
- Reuters
UPDATE 3-US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants. The advisers voted unanimously in favor of using the antibody, nirsevimab, in newborns and infants to prevent infections in their first RSV season. In a separate 19-2 vote, the panel backed the therapy's use in children aged up to two years who are vulnerable to severe illness through their second RSV season.
Motley FoolWhy Shares of Innate Pharma Jumped Thursday
Shares of Innate Pharma (NASDAQ: IPHA) were up 8% Thursday morning after rising as much as 10.6% earlier in the day after the company said the Food and Drug Administration (FDA) had granted Fast Track Designation to a cancer therapy the company is developing with Sanofi. Innate is a clinical-stage biotech company that specializes in immunotherapies to treat cancer. The company said that the FDA had given Fast Track Designation to SAR579/IPH6101 to treat certain blood cancers.
- Reuters
UPDATE 3-Sanofi-AstraZeneca's preventive RSV therapy appears safe- FDA staff
The U.S. Food and Drug Administration's staff reviewers said on Tuesday Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infections in infants appeared safe and effective. The RSV prevention antibody, nirsevimab, showed an overall favorable safety profile in clinical trials, the FDA staff said in documents published ahead of the health regulator's advisory committee meeting on Thursday to discuss the therapy's marketing application.
ZacksAre You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
ZacksSanofi (SNY) Gains But Lags Market: What You Should Know
Sanofi (SNY) closed at $51.01 in the latest trading session, marking a +1.09% move from the prior day.
FortuneGen Z needs brand-new skills to climb to the C-suite: ‘What got me here will not get them there,’ says health care CEO
Knowing how to use and implement generative A.I. will be a “minimum expectation” for future CEOs, Sanofi CEO Paul Hudson said.
ZacksPharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
ZacksThe Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge
Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge are included in this Analyst Blog.
- GlobeNewswire
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
Sanofi launches 2023 global Employee Stock Purchase Plan Paris, June 1 2023. Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 countries. The program builds on plans carried out since 2013 and demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company. Paul HudsonChief Executive Officer of Sanofi "This plan represents our
ZacksTop Stock Reports for FEMSA, NextEra Energy & Sanofi
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).
ZacksSanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Motley FoolWas This $3 Billion Deal a Wise Move for Sanofi?
The French drugmaker appears to have meaningfully improved its portfolio with the acquisition.
- GlobeNewswire
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placeboSanofi plans to initiate pivotal trials in multiple sclerosis in early 2024 Paris, May 31 2023. New data, being presented in a late-breaking session at the 2023 Consortium of
- Zacks
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
- GlobeNewswire
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors Approval of the financial statements for the fiscal year 2022Distribution of a cash dividend of €3.56 per share, with payment as of June 1st, 2023Board composition: Frédéric Oudéa becomes Independent Director and Chairman of the Board Paris, May 25, 2023. The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg. The General Meeting approved
BenzingaSanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented results from a Phase 3 study of Dupixent (dupilumab) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. Dupixent demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo, meeting the primary endpoint. Dupixent significantly improved lung
Motley Fool2 Bear Market Defying Stocks to Buy in May
This group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35.
- GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placeboDupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 w
Investopedia5 Things to Know Before Markets Open
President Biden said he was confident that negotiators would reach a deal on the debt ceiling and Fed Chair Jerome Powell is set to speak on monetary policy. Here’s what investors need to know today.
The Wall Street JournalSanofi Wins Supreme Court Patent Dispute With Amgen
The court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi.
